A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the ...

Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Swiss pharma major Roche (ROG: SIX) has outlined ambitious plans to accelerate the development of trontinemab, its ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

A new Alzheimer’s drug has been hailed as a major breakthrough after clinical trials showed it could clear the harmful brain ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Major health news includes Roche's plan to test a drug for Alzheimer's, a US data-sharing initiative in healthcare, Nordic ...